Disclaimer:
Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.
BUSPIRONE
Overview
What is BUSPIRONE?
Buspirone hydrochloride is an antianxiety agent that is not
chemically or pharmacologically related to the benzodiazepines, barbiturates, or
other sedative/anxiolytic drugs.
Buspirone hydrochloride is a white crystalline, water soluble compound and is
chemically designated as -[4-[4-(2-Pyrimidinyl)-1-piperazinyl]butyl]-1,1-cyclopentanedi-acetamide
monohydrochloride. It has the following structural formula:
CHNO•HCl M.W. 422.0
Buspirone hydrochloride is supplied as tablets for oral administration
containing 5 mg, 10 mg, or 15 mg of buspirone hydrochloride (equivalent to 4.6
mg, 9.1 mg, or 13.7 mg of buspirone free base respectively). The 5-mg and 10-mg
tablets are scored so they can be bisected. Thus, the 5-mg tablet can also
provide a 2.5-mg dose, and the 10-mg tablet can provide a 5-mg dose. The 15 mg
tablet is scored so it can be either bisected or trisected. Thus, a single 15-mg
tablet can provide the following doses: 15 mg (entire tablet), 10 mg (two-thirds
of a tablet), 7.5 mg (one-half of a tablet), or 5 mg (one-third of a tablet).
Buspirone tablets contain the following inactive ingredients: colloidal silicon
dioxide, lactose monohydrate, magnesium stearate, microcrystalline cellulose,
and sodium starch glycolate.
What does BUSPIRONE look like?
What are the available doses of BUSPIRONE?
Sorry No records found.
What should I talk to my health care provider before I take BUSPIRONE?
Sorry No records found
How should I use BUSPIRONE?
Buspirone hydrochloride tablets are indicated for the management
of anxiety disorders or the short-term relief of the symptoms of anxiety.
Anxiety or tension associated with the stress of everyday life usually does not
require treatment with an anxiolytic. The efficacy of buspirone has been
demonstrated in controlled clinical trials of outpatients whose diagnosis
roughly corresponds to Generalized Anxiety Disorder (GAD). Many of the patients
enrolled in these studies also had coexisting depressive symptoms and buspirone
relieved anxiety in the presence of these coexisting depressive symptoms. The
patients evaluated in these studies had experienced symptoms for periods of 1
month to over 1 year prior to the study, with an average symptom duration of 6
months. Generalized Anxiety Disorder (300.02) is described in the American
Psychiatric Association’s Diagnostic and Statistical Manual, III as follows: Generalized, persistent anxiety (of at least 1
month continual duration), manifested by symptoms from three of the four
following categories:
The above symptoms would not be due to another mental disorder, such as a
depressive disorder or schizophrenia. However, mild depressive symptoms are
common in GAD.
The effectiveness of buspirone in long-term use, that is, for more than 3 to
4 weeks, has not been demonstrated in controlled trials. There is no body of
evidence available that systematically addresses the appropriate duration of
treatment for GAD. However, in a study of long-term use, 264 patients were
treated with buspirone for 1 year without ill effect. Therefore, the physician
who elects to use buspirone for extended periods should periodically reassess
the usefulness of the drug for the individual patient.
The recommended initial dose is 15 mg daily (7.5 mg b.i.d.). To
achieve an optimal therapeutic response, at intervals of 2 to 3 days the dosage
may be increased 5 mg per day, as needed. The maximum daily dosage should not
exceed 60 mg per day. In clinical trials allowing dose titration, divided doses
of 20 to 30 mg per day were commonly employed.
The bioavailability of buspirone is increased when given with food as
compared to the fasted state (see ). Consequently, patients should take buspirone in a
consistent manner with regard to the timing of dosing; either always with or
always without food.
When buspirone is to be given with a potent inhibitor of CYP3A4 the dosage
recommendations described in the section should be followed.
What interacts with BUSPIRONE?
Sorry No Records found
What are the warnings of BUSPIRONE?
Sorry No Records found
What are the precautions of BUSPIRONE?
Sorry No Records found
What are the side effects of BUSPIRONE?
Sorry No records found
What should I look out for while using BUSPIRONE?
Buspirone is contraindicated in patients hypersensitive to
buspirone hydrochloride.
What might happen if I take too much BUSPIRONE?
In clinical pharmacology trials, doses as high as 375 mg/day were
administered to healthy male volunteers. As this dose was approached, the
following symptoms were observed: nausea, vomiting, dizziness, drowsiness,
miosis, and gastric distress. A few cases of overdosage have been reported, with
complete recovery as the usual outcome. No deaths have been reported following
overdosage with buspirone alone. Rare cases of intentional overdosage with a
fatal outcome were invariably associated with ingestion of multiple drugs and/or
alcohol, and a causal relationship to buspirone could not be determined.
Toxicology studies of buspirone yielded the following LD values: mice, 655 mg/kg; rats, 196 mg/kg; dogs, 586 mg/kg;
and monkeys, 356 mg/kg. These dosages are 160 to 550 times the recommended human
daily dose.
General symptomatic and supportive measures should be used along
with immediate gastric lavage. Respiration, pulse, and blood pressure should be
monitored as in all cases of drug overdosage. No specific antidote is known to
buspirone, and dialyzability of buspirone has not been determined
How should I store and handle BUSPIRONE?
Store at 25°C (77°F); excursions permitted to 15-30°C (59-86°F) [see USP Controlled Room Temperature].Keep out of reach of children.Store at 25°C (77°F); excursions permitted to 15-30°C (59-86°F) [see USP Controlled Room Temperature].Keep out of reach of children.Buspirone Hydrochloride Tablets USP are available as white, oval tablets debossed with an hourglass logo, breakline and “5” on one side, “5663” on the reverse side containing 5 mg buspirone hydrochloride, packaged in bottles of 60, 100, 500 and 1000 tablets and unit-dose boxes of 100 tablets.Buspirone Hydrochloride Tablets USP are available as white, oval tablets debossed with an hourglass logo, breakline and “10” on one side, “5664” on the reverse side containing 10 mg buspirone hydrochloride, packaged in bottles of 60, 100, 500 and 1000 tablets and unit-dose boxes of 100 tablets.Buspirone Hydrochloride Tablets USP are available as white, capsule-shaped tablets debossed with “5”, breakline, “5”, breakline, “5” on one side, an hourglass logo, breakline, “56”, breakline, “65” on the reverse side containing 15 mg buspirone hydrochloride, packaged in bottles of 60, 100, 250 and 500 tablets.PHARMACIST: Dispense in a tight, light-resistant container as defined in the USP. Use child-resistant closure (as required).Store at 20°-25°C (68°-77°F) [See USP Controlled Room Temperature].Protect from temperatures greater than 86°F (30°C).Buspirone Hydrochloride Tablets USP are available as white, oval tablets debossed with an hourglass logo, breakline and “5” on one side, “5663” on the reverse side containing 5 mg buspirone hydrochloride, packaged in bottles of 60, 100, 500 and 1000 tablets and unit-dose boxes of 100 tablets.Buspirone Hydrochloride Tablets USP are available as white, oval tablets debossed with an hourglass logo, breakline and “10” on one side, “5664” on the reverse side containing 10 mg buspirone hydrochloride, packaged in bottles of 60, 100, 500 and 1000 tablets and unit-dose boxes of 100 tablets.Buspirone Hydrochloride Tablets USP are available as white, capsule-shaped tablets debossed with “5”, breakline, “5”, breakline, “5” on one side, an hourglass logo, breakline, “56”, breakline, “65” on the reverse side containing 15 mg buspirone hydrochloride, packaged in bottles of 60, 100, 250 and 500 tablets.PHARMACIST: Dispense in a tight, light-resistant container as defined in the USP. Use child-resistant closure (as required).Store at 20°-25°C (68°-77°F) [See USP Controlled Room Temperature].Protect from temperatures greater than 86°F (30°C).Buspirone Hydrochloride Tablets USP are available as white, oval tablets debossed with an hourglass logo, breakline and “5” on one side, “5663” on the reverse side containing 5 mg buspirone hydrochloride, packaged in bottles of 60, 100, 500 and 1000 tablets and unit-dose boxes of 100 tablets.Buspirone Hydrochloride Tablets USP are available as white, oval tablets debossed with an hourglass logo, breakline and “10” on one side, “5664” on the reverse side containing 10 mg buspirone hydrochloride, packaged in bottles of 60, 100, 500 and 1000 tablets and unit-dose boxes of 100 tablets.Buspirone Hydrochloride Tablets USP are available as white, capsule-shaped tablets debossed with “5”, breakline, “5”, breakline, “5” on one side, an hourglass logo, breakline, “56”, breakline, “65” on the reverse side containing 15 mg buspirone hydrochloride, packaged in bottles of 60, 100, 250 and 500 tablets.PHARMACIST: Dispense in a tight, light-resistant container as defined in the USP. Use child-resistant closure (as required).Store at 20°-25°C (68°-77°F) [See USP Controlled Room Temperature].Protect from temperatures greater than 86°F (30°C).Buspirone Hydrochloride Tablets USP are available as white, oval tablets debossed with an hourglass logo, breakline and “5” on one side, “5663” on the reverse side containing 5 mg buspirone hydrochloride, packaged in bottles of 60, 100, 500 and 1000 tablets and unit-dose boxes of 100 tablets.Buspirone Hydrochloride Tablets USP are available as white, oval tablets debossed with an hourglass logo, breakline and “10” on one side, “5664” on the reverse side containing 10 mg buspirone hydrochloride, packaged in bottles of 60, 100, 500 and 1000 tablets and unit-dose boxes of 100 tablets.Buspirone Hydrochloride Tablets USP are available as white, capsule-shaped tablets debossed with “5”, breakline, “5”, breakline, “5” on one side, an hourglass logo, breakline, “56”, breakline, “65” on the reverse side containing 15 mg buspirone hydrochloride, packaged in bottles of 60, 100, 250 and 500 tablets.PHARMACIST: Dispense in a tight, light-resistant container as defined in the USP. Use child-resistant closure (as required).Store at 20°-25°C (68°-77°F) [See USP Controlled Room Temperature].Protect from temperatures greater than 86°F (30°C).Buspirone Hydrochloride Tablets USP are available as white, oval tablets debossed with an hourglass logo, breakline and “5” on one side, “5663” on the reverse side containing 5 mg buspirone hydrochloride, packaged in bottles of 60, 100, 500 and 1000 tablets and unit-dose boxes of 100 tablets.Buspirone Hydrochloride Tablets USP are available as white, oval tablets debossed with an hourglass logo, breakline and “10” on one side, “5664” on the reverse side containing 10 mg buspirone hydrochloride, packaged in bottles of 60, 100, 500 and 1000 tablets and unit-dose boxes of 100 tablets.Buspirone Hydrochloride Tablets USP are available as white, capsule-shaped tablets debossed with “5”, breakline, “5”, breakline, “5” on one side, an hourglass logo, breakline, “56”, breakline, “65” on the reverse side containing 15 mg buspirone hydrochloride, packaged in bottles of 60, 100, 250 and 500 tablets.PHARMACIST: Dispense in a tight, light-resistant container as defined in the USP. Use child-resistant closure (as required).Store at 20°-25°C (68°-77°F) [See USP Controlled Room Temperature].Protect from temperatures greater than 86°F (30°C).Buspirone Hydrochloride Tablets USP are available as white, oval tablets debossed with an hourglass logo, breakline and “5” on one side, “5663” on the reverse side containing 5 mg buspirone hydrochloride, packaged in bottles of 60, 100, 500 and 1000 tablets and unit-dose boxes of 100 tablets.Buspirone Hydrochloride Tablets USP are available as white, oval tablets debossed with an hourglass logo, breakline and “10” on one side, “5664” on the reverse side containing 10 mg buspirone hydrochloride, packaged in bottles of 60, 100, 500 and 1000 tablets and unit-dose boxes of 100 tablets.Buspirone Hydrochloride Tablets USP are available as white, capsule-shaped tablets debossed with “5”, breakline, “5”, breakline, “5” on one side, an hourglass logo, breakline, “56”, breakline, “65” on the reverse side containing 15 mg buspirone hydrochloride, packaged in bottles of 60, 100, 250 and 500 tablets.PHARMACIST: Dispense in a tight, light-resistant container as defined in the USP. Use child-resistant closure (as required).Store at 20°-25°C (68°-77°F) [See USP Controlled Room Temperature].Protect from temperatures greater than 86°F (30°C).
Clinical Information
Chemical Structure
No Image foundClinical Pharmacology
The mechanism of action of buspirone is unknown. Buspirone
differs from typical benzodiazepine anxiolytics in that it does not exert
anticonvulsant or muscle relaxant effects. It also lacks the prominent sedative
effect that is associated with more typical anxiolytics. preclinical studies have shown that buspirone has a high affinity
for serotonin (5-HT) receptors. Buspirone has no
significant affinity for benzodiazepine receptors and does not affect GABA
binding or when tested in preclinical models.
Buspirone has moderate affinity for brain D-dopamine
receptors. Some studies do suggest that buspirone may have indirect effects on
other neurotransmitter systems.
Buspirone is rapidly absorbed in man and undergoes extensive first-pass
metabolism. In a radiolabeled study, unchanged buspirone in the plasma accounted
for only about 1% of the radioactivity in the plasma. Following oral
administration, plasma concentrations of unchanged buspirone are very low and
variable between subjects. Peak plasma levels of 1 to 6 ng/mL have been observed
40 to 90 minutes after single oral doses of 20 mg. The single-dose
bioavailability of unchanged buspirone when taken as a tablet is on the average
about 90% of an equivalent dose of solution, but there is large variability.
The effects of food upon the bioavailability of buspirone have been studied
in eight subjects. They were given a 20-mg dose with and without food; the area
under the plasma concentration-time curve (AUC) and peak plasma concentration
(C) of unchanged buspirone increased by 84% and 116%
respectively, but the total amount of buspirone immunoreactive material did not
change. This suggests that food may decrease the extent of presystemic clearance
of buspirone. (see ).
A multiple-dose study conducted in 15 subjects suggests that buspirone has
nonlinear pharmacokinetics. Thus, dose increases and repeated dosing may lead to
somewhat higher blood levels of unchanged buspirone than would be predicted from
results of single-dose studies.
An protein binding study indicated that
approximately 86% of buspirone is bound to plasma proteins. It was also observed
that aspirin increased the plasma levels of free buspirone by 23%, while
flurazepam decreased the plasma levels of free buspirone by 20%. However, it is
not known whether these drugs cause similar effects on plasma levels of free
buspirone , or whether such changes, if they
do occur, cause clinically significant differences in treatment outcome. An
study indicated that buspirone did not
displace highly protein-bound drugs such as phenytoin, warfarin, and propranolol
from plasma protein, and that buspirone may displace digoxin.
Buspirone is metabolized primarily by oxidation, which has been shown to be mediated by cytochrome P450 3A4 (CYP3A4). (see
). Several hydroxylated
derivatives and a pharmacologically active metabolite, 1-pyrimidinylpiperazine
(1-PP), are produced. In animal models predictive of anxiolytic potential, 1-PP
has about one-quarter of the activity of buspirone, but is present in up to
20-fold greater amounts. However, this is probably not important in humans:
blood samples from humans chronically exposed to buspirone do not exhibit high
levels of 1-PP; mean values are approximately 3 ng/mL and the highest human
blood level recorded among 108 chronically dosed patients was 17 ng/mL, less
than 1/200th of 1-PP levels found in animals given large doses of buspirone
without signs of toxicity.
In a single-dose study using C-labeled buspirone,
29% to 63% of the dose was excreted in the urine within 24 hours, primarily as
metabolites; fecal excretion accounted for 18% to 38% of the dose. The average
elimination half-life of unchanged buspirone after single doses of 10 to 40 mg
is about 2 to 3 hours.
After single or multiple doses in adults, no significant
differences in buspirone pharmacokinetics (AUC and C)
were observed between elderly and younger subjects or between men and
women.
After multiple-dose administration of buspirone to patients with
hepatic impairment, steady-state AUC of buspirone increased 13-fold compared
with healthy subjects (see ).
After multiple-dose administration of buspirone to renally
impaired (Cl=10-70 mL/min/1.73 m) patients, steady-state AUC of buspirone increased 4-fold
compared with healthy (Cl>/= 80 mL/min/1.73 m) subjects (see ).
The effects of race on the pharmacokinetics of buspirone have not
been studied.
Non-Clinical Toxicology
Buspirone is contraindicated in patients hypersensitive to buspirone hydrochloride.Patients who are taking non-selective beta blockers may be more reactive to skin tests and may be unresponsive to the usual doses of epinephrine used to treat allergic reactions. Antihistamines can significantly inhibit the immediate skin test reactions. If long acting antihistamines have been taken recently, it is recommended that they should be stopped for the following minimum intervals before skin testing is performed: at least 1 month for astemizole; 1 week for hydroxyzine or cetirizine; 4 to 7 days for Ioratadine; 3 to 4 days for terfenadine or fexofenadine; and 24 to 48 hours for other sustained release antihistamines. (6)
The administration of buspirone to a patient taking a monoamine oxidase inhibitor (MAOI) may pose a hazard.
Because buspirone has no established antipsychotic activity, it should not be employed in lieu of appropriate antipsychotic treatment.
Studies indicate that buspirone is less sedating than other anxiolytics and that it does not produce significant functional impairment. However, its CNS effects in any individual patient may not be predictable. Therefore, patients should be cautioned about operating an automobile or using complex machinery until they are reasonably certain that buspirone treatment does not affect them adversely.
While formal studies of the interaction of buspirone with alcohol indicate that buspirone does not increase alcohol-induced impairment in motor and mental performance, it is prudent to avoid concomitant use of alcohol and buspirone.
Because buspirone does not exhibit cross-tolerance with benzodiazepines and other common sedative/hypnotic drugs, it will not block the withdrawal syndrome often seen with cessation of therapy with these drugs. Therefore, before starting therapy with buspirone, it is advisable to withdraw patients gradually, especially patients who have been using a CNS-depressant drug chronically, from their prior treatment. Rebound or withdrawal symptoms may occur over varying time periods, depending in part on the type of drug, and its effective half-life of elimination.
The syndrome of withdrawal from sedative/hypnotic/anxiolytic drugs can appear as any combination of irritability, anxiety, agitation, insomnia, tremor, abdominal cramps, muscle cramps, vomiting, sweating, flu-like symptoms without fever, and occasionally, even as seizures.
Because buspirone can bind to central dopamine receptors, a question has been raised about its potential to cause acute and chronic changes in dopamine-mediated neurological function (e.g., dystonia, pseudo-parkinsonism, akathisia, and tardive dyskinesia). Clinical experience in controlled trials has failed to identify any significant neuroleptic-like activity; however, a syndrome of restlessness, appearing shortly after initiation of treatment, has been reported in some small fraction of buspirone-treated patients. The syndrome may be explained in several ways. For example, buspirone may increase central noradrenergic activity; alternatively, the effect may be attributable to dopaminergic effects (i.e., represent akathisia). Obviously, the question cannot be totally resolved at this point in time. Generally, long-term sequelae of any drug’s use can be identified only after several years of marketing.
(
See also PRECAUTIONS
)
The more commonly observed untoward events associated with the use of buspirone not seen at an equivalent incidence among placebo-treated patients include dizziness, nausea, headache, nervousness, lightheadedness, and excitement.
One guide to the relative clinical importance of adverse events associated with buspirone is provided by the frequency with which they caused drug discontinuation during clinical testing. Approximately 10% of the 2200 anxious patients who participated in the buspirone premarketing clinical efficacy trials in anxiety disorders lasting 3 to 4 weeks discontinued treatment due to an adverse event. The more common events causing discontinuation included: central nervous system disturbances (3.4%), primarily dizziness, insomnia, nervousness, drowsiness, and lightheaded feeling; gastrointestinal disturbances (1.2%), primarily nausea; and miscellaneous disturbances (1.1%), primarily headache and fatigue. In addition, 3.4% of patients had multiple complaints, none of which could be characterized as primary.
The table that follows enumerates adverse events that occurred at a frequency of 1% or more among buspirone patients who participated in 4-week, controlled trials comparing buspirone with placebo. The frequencies were obtained from pooled data for 17 trials. The prescriber should be aware that these figures cannot be used to predict the incidence of side effects in the course of usual medical practice where patient characteristics and other factors differ from those which prevailed in the clinical trials. Similarly, the cited frequencies cannot be compared with figures obtained from other clinical investigations involving different treatments, uses, and investigators. Comparison of the cited figures, however, does provide the prescribing physician with some basis for estimating the relative contribution of drug and nondrug factors to the side-effect incidence rate in the population studied.
TREATMENT-EMERGENT ADVERSE EXPERIENCE INCIDENCE IN PLACEBO-CONTROLLED CLINICAL TRIALS*(Percent of Patients Reporting)
During its premarketing assessment, buspirone was evaluated in over 3500 subjects. This section reports event frequencies for adverse events occurring in approximately 3000 subjects from this group who took multiple doses of buspirone in the dose range for which buspirone is being recommended (i.e., the modal daily dose of buspirone fell between 10 and 30 mg for 70% of the patients studied) and for whom safety data were systematically collected. The conditions and duration of exposure to buspirone varied greatly, involving well-controlled studies as well as experience in open and uncontrolled clinical settings. As part of the total experience gained in clinical studies, various adverse events were reported. In the absence of appropriate controls in some of the studies, a causal relationship to buspirone hydrochloride, treatment cannot be determined. The list includes all undesirable events reasonably associated with the use of the drug.
The following enumeration by organ system describes events in terms of their relative frequency of reporting in this database.
Events of major clinical importance are also described in the section.
The following definitions of frequency are used: Frequent adverse events are defined as those occurring in at least 1/100 patients. Infrequent adverse events are those occurring in 1/100 to 1/1000 patients, while rare events are those occurring in less than 1/1000 patients.
Frequent was nonspecific chest pain; infrequent were syncope, hypotension, and hypertension; rare were cerebrovascular accident, congestive heart failure, myocardial infarction, cardiomyopathy, and bradycardia.
Frequent were dream disturbances; infrequent were depersonalization, dysphoria, noise intolerance, euphoria, akathisia, fearfulness, loss of interest, dissociative reaction, hallucinations, involuntary movements, slowed reaction time, suicidal ideation, and seizures; rare were feelings of claustrophobia, cold intolerance, stupor, and slurred speech and psychosis.
Frequent were tinnitus, sore throat, and nasal congestion; infrequent were redness and itching of the eyes, altered taste, altered smell, and conjunctivitis; rare were inner ear abnormality, eye pain, photophobia, and pressure on eyes.
Rare were galactorrhea and thyroid abnormality.
Infrequent were flatulence, anorexia, increased appetite, salivation, irritable colon, and rectal bleeding; rare was burning of the tongue.
Infrequent were urinary frequency, urinary hesitancy, menstrual irregularity and spotting, and dysuria; rare were amenorrhea, pelvic inflammatory disease, enuresis, and nocturia.
Infrequent were muscle cramps, muscle spasms, rigid/stiff muscles, and arthralgias; rare was muscle weakness.
Infrequent were hyperventilation, shortness of breath, and chest congestion; rare was epistaxis
Infrequent were decreased or increased libido; rare were delayed ejaculation and impotence.
Infrequent were edema, pruritus, flushing, easy bruising, hair loss, dry skin, facial edema, and blisters; rare were acne and thinning of nails.
Infrequent were increases in hepatic aminotransferases (SGOT, SGPT); rare were eosinophilia, leukopenia, and thrombocytopenia.
Infrequent were weight gain, fever, roaring sensation in the head, weight loss, and malaise; rare were alcohol abuse, bleeding disturbance, loss of voice, and hiccoughs.
Postmarketing experience has shown an adverse experience profile similar to that given above. Voluntary reports since introduction have included rare occurrences of allergic reactions (including urticaria), angioedema, cogwheel rigidity, dizziness (rarely reported as vertigo), dystonic reactions, ataxias, extrapyramidal symptoms, dyskinesias (acute and tardive), ecchymosis, emotional lability, serotonin syndrome, transient difficulty with recall, urinary retention, and visual changes (including tunnel vision). Because of the uncontrolled nature of these spontaneous reports, a causal relationship to buspirone treatment has not been determined
Reference
This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"
While we update our database periodically, we cannot guarantee it is always updated to the latest version.
Review
Read user comments about the side effects, benefits, and effectiveness of losartan oral.
Overall User Ratings
514Total User Reviews
User Reviews
Learn about
User Reviews
Professional
Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72Tips
Tips
Interactions
Interactions
A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).